The identifi cation of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofi brosis and improves overall survival; however, the mechanism by which JAK inhibitors achieve effi cacy has not been delineated. Patients with MPN present with increased levels of circulating proinfl ammatory cytokines, which are mitigated by JAK inhibitor therapy. We sought to elucidate mechanisms by which JAK inhibitors attenuate cytokine-mediated pathophysiology. Single-cell profi ling demonstrated that hematopoietic cells from myelofi brosis models and patient samples aberrantly secrete infl ammatory cytokines. Panhematopoietic Stat3 deletion reduced disease severity and attenuated cytokine secretion, with similar effi cacy as observed with ruxolitinib therapy. In contrast, Stat3 deletion restricted to MPN cells did not reduce disease severity or cytokine production. Consistent with these observations, we found that malignant and nonmalignant cells aberrantly secrete cytokines and JAK inhibition reduces cytokine production from both populations.
INTRODUCTION
Myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders characterized by the proliferation of one or more myeloid lineages ( 1 ) . Patients with MPN develop progressive splenomegaly, thrombosis, bleeding, and/or infection. Patients with MPN are also at cumulative risk to develop progressive bone marrow failure and/or transform to acute myeloid leukemia (AML), conditions which are associated with dismal clinical outcome ( 2 ) . The discovery of cytokine-independent colony formation of MPN progenitors suggested that constitutive cytokine signaling contributes to MPN pathogenesis ( 3 ) . The observation of somatic activating JAK2 V617F mutations in patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofi brosis (PMF) provided the fi rst insight into the molecular basis of MPN (4) (5) (6) (7) . Subsequent studies identifi ed somatic JAK-STAT pathway mutations in JAK2 V617F -negative MPN, most commonly in the CALR gene ( 8, 9 ) and the thrombopoietin receptor ( MPL W515L ; ref. 10 ) . These data underscore the central importance of genetic alterations in the JAK-STAT signaling pathway in MPN pathogenesis.
The discovery of JAK2/MPL mutations in the majority of patients with MPN provided the rationale for the clinical development of JAK kinase inhibitors for patients with MPN and subsequently for other malignancies. Clinical studies with JAK kinase inhibitors have shown that these agents improve splenomegaly, systemic symptoms, and overall survival ( 11 ) . On the basis of these data, ruxolitinib, a JAK1/JAK2 kinase inhibitor, was approved for patients with myelofi brosis, and several other JAK inhibitors are in late-phase clinical trials. Although JAK inhibitors offer substantial clinical benefi t to patients with MPN, the mechanisms by which these agents achieve clinical effi cacy have not been fully delineated. Patients with MPN have signifi cantly elevated circulating levels of proinfl ammatory cytokines, and increased circulating cytokine levels are associated with adverse survival in myelofi brosis ( 12 ) . It has been hypothesized that the cytokine-driven infl ammatory state in MPN contributes to the constitutional symptoms, bone marrow fi brosis, extramedullary hematopoiesis, and disease progression characteristic of these myeloid malignancies. JAK inhibitor therapy with ruxolitinib is associated with a reduction in the level of proinfl ammatory cytokines ( 13 ) ; however, the role of aberrant cytokine production in
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myelofi brosis pathogenesis and in the response to JAK inhibitors remains to be delineated. We therefore sought to elucidate the role of aberrant cytokine production in MPN pathogenesis and in the response to JAK kinase inhibitors. We used a novel microfl uidic single-cell profi ling technique to examine the cytokine secretion profi les of myelofi brosis cells on a single-cell level and show that a signifi cantly greater degree of multifunctionality and heterogeneity in cytokine production is a characteristic feature of myelofi brosis cells. Moreover, we show that JAK-STAT signaling in nonmutant hematopoietic cells contributes to MPN pathogenesis and that inhibition of JAK-STAT signaling in both mutant and nonmutant cells is required to reduce infl ammatory signaling and to achieve clinical benefi t in MPNs.
RESULTS

Proinfl ammatory Cytokines Are Elevated in Myelofi brosis Mice and Reversed with JAK1/2 Inhibitor Treatment
To identify cytokines that are altered in myelofi brosis, we measured the serum levels of 32 cytokines in the MPL W515L bone marrow transplant myelofi brosis model ( 14 ) using multiplex bead-based Luminex technology. We identifi ed a set of infl ammatory cytokines, including IL6, CXCL9, and CCL2, which are elevated in the serum of MPL W515L -mutant diseased mice ( Fig. 1A ) , similar to the alterations in circulating cytokines observed in patients with myelofi brosis ( 12, 13 ) . Ruxolitinib treatment (90 mg/kg, twice a day ) normalized cytokine levels, consistent with the effects seen with chronic JAK inhibition in patients with MPN ( Fig. 1A and Supplementary Fig. S1 ; ref. 13 ) . Circulating cytokine levels were also elevated in myelofi brotic (6-month-old) Jak2
V617F
;Vav-Cre knockin mice ( Fig. 1B ; ref. 15 ) , and ruxolitinib treatment (60 mg/kg, twice a day) normalized cytokine levels in mice transplanted with Jak2 V617F -mutant cells ( Fig. 1C ) . Short-term ruxolitinib treatment (3 doses, 90 mg/kg, twice a day) reduced cytokine production to a similar extent to that observed with 14 days of ruxolitinib treatment (90 mg/kg, twice a day; Fig. 1D ), consistent with the rapid improvements in symptoms and splenomegaly seen with JAK inhibitor therapy ( 13 ) and with a direct effect of JAK kinase inhibition on cytokine secretion. The majority of cytokines (7 of 8) were also increased in the bone marrow supernatant ( Fig. 1E ) of MPL W515L -mutant diseased 
;Vav -Cre + cells. n = 4. *, P < 0.05. C, log 2 fold changes in serum cytokine levels in primary JAK2 V617F knockin mice (late-stage disease) compared with age-matched littermate controls are shown. Mean ± SEM, n = 9 in each group. D, short-term treatment (3 doses, 90 mg/kg, twice a day) with ruxolitinib effi ciently reduces serum cytokine levels in MPL W515L -mutant diseased mice. Log 2 fold changes are displayed. n = 4. *, P < 0.05. E, log 2 fold changes in serum and bone marrow (BM) supernatant in MPL W515L mice compared with MigR1 mice. Mean ± SEM. 
Ruxolitinib 90 mg/kg 3 doses Ruxolitinib 90 mg/kg 2 weeks (b.i.d.)
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mice, suggesting that aberrant cytokine production in myelofi brosis is, at least in part, derived from bone marrow cells.
Bone Marrow Myelofi brosis Cells Feature Aberrant Cytokine Secretion Profi les
To evaluate whether bone marrow cells are the source of aberrant cytokine production in myelofi brosis, we optimized a microchip system that allowed us to perform multiplexed measurements of up to 15 secretory cytokines from primary murine and human bone marrow cells at single-cell resolution ( Fig. 2A ; refs. [16] [17] [18] . Hierarchical cluster analysis of the single-cell secretomic profi les delineated multiple distinct populations that displayed heterogeneous secretion signatures and revealed marked differences between myelofi brosis and control bone marrow cells ( Fig. 2A ) . We observed a significant increase in the fraction of cytokine-secreting cells and in the extent of cytokine secretion per single myelofi brosis cell ( Fig. 2B ) . These data suggest the increased cytokine production in myelofi brosis results from increased per-cell cytokine secretion and from an increase in the fraction of cytokinesecreting cells ( Fig. 2C ). The proportion of cells secreting at least one cytokine was signifi cantly higher in myelofi brosis mice compared with control mice (67.6% vs. 46.6%; P < 0.001; Fisher exact test). The majority of cytokine-secreting control bone marrow cells (73%) secreted less than two cytokines, consistent with physiologic secretion of one cytokine per cell. In contrast, we found that bone marrow cells from myelofi brosis mice were composed of a signifi cantly elevated frequency of multifunctional cells that cosecrete multiple cytokines: 43.9% of cells from myelofi brosis mice secreted two or more cytokines and 15.6% of cells secreted four or more cytokines compared with 1.2% in control mice ( Fig. 2D ) .
To determine which cytokines were most frequently cosecreted by myelofi brosis cells, we calculated a mutual exclusivity P value for each pair of secreted cytokines ( Fig. 2E ) . CCL3, CCL4, and TNFα were commonly cosecreted in myelofi brosis cells, and secretion of these cytokines was inversely correlated with the secretion of other cytokines ( Fig. 2F ) . We observed cosecretion of all other cytokine combinations (IL6, IL12, IL10, CCL2, CCL5, CXCL9, and CXCL1) in myelofi brosis cells, consistent with the presence of at least two distinct populations of cytokine-secreting cells in myelofi brosis. In line with these observations, principal component analysis (PCA) demonstrated that a large proportion of normal bone marrow cells did not secrete any protein and other smaller subsets with distinct secretion patterns produced only one or two cytokines, most notably, CCL3 and CCL4 ( Fig. 2G and Supplementary  Fig. S2 ). In contrast, PCA maps of myelofi brosis bone marrow cells showed multiple, large populations with heterogeneous secretion signatures. We then used the Simpson diversity index to quantify the extent of heterogeneity in cytokine secretion, and found that this index increased signifi cantly from 0.68 in normal cells to 0.85 in myelofi brosis cells ( P < 0.001), consistent with a marked increase in the heterogeneity of single-cell cytokine secretion in myelofi brosis.
Mature Myeloid and Progenitor Cells Contribute to Aberrant Cytokine Levels In Vivo
We next sought to defi ne which hematopoietic compartments contribute to aberrant cytokine secretion in myelofi brosis. We used the single-cell platform to profi le mature myeloid cells (CD11b/Gr1 double-positive) and megakaryocyte/erythroid progenitor (MEP) cells from myelofi brosis and control mice. Similar to unfractionated bone marrow cells, GFP-positive myelofi brosis myeloid cells and MEP cells had an increase in the fraction of cytokine-secreting cells and increased cytokine secretion per cell ( Supplementary  Fig. S3 ). PCA analysis showed that each population had distinct cytokine secretion profi les ( Fig. 3A ) . IL6 and IL10 were mainly secreted by MEPs, and mature myeloid cells were the main source of TNFα and CCL3 ( Fig. 3B and Supplementary  Fig. S3 ). These data indicate that different cell types have distinct cytokine secretion profi les and potentially distinct roles in myelofi brosis pathogenesis.
Aberrant Single-Cell Cytokine Secretion in PMF Cells
We next performed single-cell profi ling of circulating granulocytes from patients with myelofi brosis and healthy individuals (Supplementary Table S1 ). The average secretion level of different cytokines was signifi cantly elevated in myelofi brosis cells, resulting from both an increase in the fraction of cells secreting specifi c cytokines and the secretion level of individual cytokines per cell ( Fig. 3C and D ) . Six out of eight cytokines (IL6, IL10, IL12, TNFα, CCL2, and CCL5), which were aberrantly secreted in our murine myelofi brosis model, were also secreted at a much higher level by PMF patient cells. We observed that IL8 was most highly secreted by myelofi brosis granulocytes; previous studies have shown that increased serum IL8 levels are associated with adverse outcome in myelofi brosis ( 12 ) . Immunohistochemical analysis confi rmed increased IL8 expression in myelofi brosis bone marrow sections, whereas control bone marrow cells showed only weak expression of IL8 ( Supplementary Fig. S4 ). The proportion of cells secreting at least one cytokine was significantly increased in human myelofi brosis cells compared with control cells (41.4% vs. 14.6%; P < 0.001; Fisher exact test; Fig. 3E ), demonstrating similar patterns of cytokine secretion in patients with myelofi brosis and murine models. Altogether, our single-cell profi ling studies highlight the striking heterogeneity and multifunctionality in cytokine secretion profi le in myelofi brosis.
Deletion of Il6 from the Mouse System Shows Only Minor Effects on Mpl
W515L -Driven Disease
Previous studies of cytokine signaling in cancer have largely focused on IL6 as a mediator of infl ammation in leukemia and other malignancies ( 19 ) . Given that we found a signifi cant increase in IL6 secretion in both MPN models and myelofi brosis patient cells, we fi rst investigated the effects of Il6 deletion on MPL W515L -induced myelofi brosis in vivo . We assessed the specifi c role of IL6 in myelofi brosis in vivo by transplanting IL6-defi cient myelofi brosis cells into IL6-defi cient recipients. Il6 deletion led to a modest reduction in white blood cell (WBC) count, but did not reduce spleen weight or the extent of myeloproliferation in vivo ( Supplementary Fig. S5A and S5B). No signifi cant differences were observed in the proportion of CD11b/Gr1 double-positive cells in the target organs ( Supplementary Fig. S5C and S5D ). Consistent with these data, we found that the serum levels of other proinfl ammatory CCL2  CCL2  IL6  CXCL1  CXCL1  CCL5  CCL5  IL12  IL10  IL12  CXCL9  CXCL9  CCL4  CCL4  CCL3  CCL3  TNFα  TNFα   TNFα No significant association Co-occurrance * **** **** * *** ** *** **** **** **** * * * * *** **** **** **** ** * **** **** **** * **** **** * * *** **** **** * ** * **** *** **** * **** *** **** **** **** **** **** **** ** **** **** *** * * ** **** * * ** *** *** **** **** **** **** **** ** **** **** **** ** **** * **** **** **** **** 
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cytokines remained elevated in IL6-defi cient myelofi brosis mice, and we observed compensatory increases in IL4 and IL5 serum levels in the absence of IL6 production (Supplementary Fig. S5E and S5F ). Although the specifi c role of other cytokines in myelofi brosis requires further investigation, these data suggest that infl ammatory signaling in MPN is driven by multiple cytokines, and that inhibiting secretion or signaling of an individual cytokine cannot attenuate the cytokinesignaling loop contributing to MPN pathogenesis.
Deletion of Stat3 Reduces Cytokine Production and Ameliorates Myelofi brosis In Vivo
We next aimed to investigate whether there are specifi c signaling pathways driving cytokine production in vivo in myelofi brosis. First, to better characterize oncogenic signaling pathways activated by JAK2/MPL alleles in vitro and identify potential signaling effectors, we generated isogenic cell lines expressing the most common JAK2 and MPL mutations observed in patients with MPN. Notably, Ba/F3 cells expressing MPL W515L or MPL
W515L
-JAK2 V617F showed evidence of constitutive STAT3 activation (Supplementary Fig. S6 ). We also observed increased STAT3 phosphorylation in splenocytes from MPL W515L -diseased mice and in the bone marrow of patients with PMF ( Supplementary Fig. S7 ). JAK inhibitor therapy reduced STAT3 phosphorylation in vivo ( Fig. 4A ) .
Previous studies have shown that STAT3 signaling contributes to cytokine production in different malignant and infl ammatory contexts ( 20 ) ; however, the role of STAT3 Fold change in serum cytokine levels compared with control 40,000 8 Fig. S8 ). Stat3 deletion improved survival, reduced disease severity, and reduced cytokine-mediated infl ammation, similar to the effects observed with ruxolitinib therapy. Stat3 deletion resulted in lower white blood counts, lower spleen weights, and a reduced degree of reticulin fi brosis ( Fig. 4B-F and Supplementary Fig. S6) , and decreased the proportion of MEP cells in spleen and bone marrow ( Fig. 4G ) . Similar effects of Stat3 deletion were seen with Mx-Cre and Vav-Cre , and with somatic deletion of Stat3 after bone marrow transplantation ( Supplementary Fig. S9 ). Most importantly, hematopoietic specifi c Stat3 deletion normalized circulating cytokine levels ( Fig. 4H ) , with similar reductions in cytokine levels as with ruxolitinib therapy. These data demonstrate that STAT3 activation is required for cytokine production in myelofi brosis, and Stat3 deletion phenocopies the effects of ruxolitinib on cytokine production and on disease sequelae in vivo. Fig. 5A and B ) . In contrast to the 
Mutant-Specifi c Stat3 Deletion Does Not Reduce Infl ammatory Signaling or Myelofi brosis In Vivo
It is currently not known if JAK inhibitors achieve clinical benefi t solely from target inhibition in MPN cells, or if JAK-STAT inhibition in nonmalignant cells contributes to therapeutic effi cacy. We therefore examined whether restricting Stat3 deletion to mutant hematopoietic cells would result in similar effects as pan-hematopoietic Stat3 deletion. We transplanted lethally irradiated CD45.1-positive recipient mice with MPL W515L -positive, Stat3 -deleted bone marrow (CD45.2-positive) along with Stat3 wild-type support marrow (CD45.1-positive;
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signifi cant effects seen with complete hematopoietic Stat3 deletion, MPN-specifi c Stat3 deletion did not reduce disease severity ( Fig. 5C and D and Supplementary Fig. S10 ). Consistent with these data, MPN-specifi c Stat3 deletion did not signifi cantly attenuate cytokine production, in contrast to the effects observed with pan-hematopoietic Stat3 deletion ( Fig. 5E ). These data are consistent with a requirement for STAT3 signaling in both malignant and nonmalignant hematopoietic cells in myelofi brosis.
Cytokine Production in Myelofi brosis Originates in Malignant and Nonmalignant Hematopoietic Cells
The genetic studies described above suggested that aberrant cytokine production in myelofi brosis emanates from malignant and nonmalignant hematopoietic cells. We therefore analyzed cytokine mRNA expression in sorted MPL W515L -mutant (GFP-positive) and wild-type (GFP-negative) bone marrow cells using NanoString technology. We found that MPL W515L -mutant myelofi brosis cells express high mRNA levels of a subset of infl ammatory cytokines, including Il6 , consistent with tumor-derived cytokine production ( Fig. 6A ) . In contrast, we found that some cytokines, including Ccl2 and Tnfa , were derived from both GFP-positive and GFP-negative populations, and other cytokines, including Il12 and Cxcl9 , were largely derived from nonmutant cells ( Fig. 6A ) .
We then performed single-cell analysis of sorted mutant and wild-type subpopulations to further delineate the contribution of malignant and nonmalignant cells to cytokine production. Single-cell analysis of lineage-positive (mature) and lineage-negative [hematopoeitic stem/progenitor (HSPC)] cells revealed that GFP-positive and GFP-negative cells from mature and HSPC compartments aberrantly secrete cytokines in myelofi brosis ( Fig. 6B and C ) . We observed an increase in cytokine secretion and in the degree of single-cell cytokine secretion heterogeneity in both GFP-positive and GFP-negative cells from stem/progenitor and differentiated cells compared with control bone marrow cells (Supplementary Fig. S11 ). MPL W515L -mutant HSPCs were the largest source of IL6, whereas nonmutant mature cells were the primary source of CXCL9 ( Fig. 6B ). Mutant and wild-type cells both secreted TNFα, IL10, and CCL2 consistent with production by multiple populations ( Fig. 6C ) . We observed an increase in total cytokine production and an increase in the proportion of cells which secreted multiple cytokines in GFP-positive/negative mature and GFP-positive HSPC from myelofi brosis mice ( Fig. 6D and Supplementary Figs. S11 and S12). Importantly, ruxolitinib treatment normalized cytokine expression from GFP-positive and GFP-negative cell populations ( Fig. 6E ) , demonstrating that JAK inhibition reduces cytokine production from both tumor and nontumor populations in vivo .
We next sought to extend our fi ndings to JAK2 V617F -mutant MPN. We transplanted whole bone marrow of Jak2 V617F ;Vav-Cre knockin mice (CD45.2) with CD45.1 wildtype support marrow into CD45.1-recipient mice (MPN mice). After all mice were engrafted with JAK2 V617F -positive disease, we performed single-cell cytokine analysis on sorted CD45.2 and CD45.1 cells to elucidate cytokine secretion in mutant and nonmutant cells ( Fig. 7A ) . As a control, we transplanted wild-type CD45.2 bone marrow with CD45.1 support cells into CD45.1-recipient mice (control mice). Single-cell cytokine profi ling revealed marked differences in cytokine secretion in bone marrow cells derived from MPN and control mice (Supplementary Fig. S13 ). Most importantly, this included aberrant cytokine production in CD45.2-mutant and CD45.1-nonmutant cells from MPN mice. We observed an increase in the fraction of cytokinesecreting cells and in the extent of cytokine secretion per single cell in mutant and nonmutant hematopoietic populations from Jak2 -mutant MPN mice ( Fig. 7B and C and Supplementary Fig. S14 ). The proportion of cells secreting at least one cytokine was signifi cantly higher within the wild-type population (CD45.1) of myelofi brosis mice compared with the CD45.1 population of control mice (47.1% vs. 27%; P < 0.001; Fisher exact test; Fig. 7D ). Similarly, 65% of CD45.2-positive JAK2 V617F -expressing cells from myelofibrosis mice secreted at least one cytokine compared with only 28.5% of control CD45.2 cells ( P < 0.001; Fisher exact test). Furthermore, Jak2
V617F -negative CD45.1-positive and Jak2 V617F -positive CD45.2-positive bone marrow cells from myelofi brosis exhibited a marked increase in the proportion of multifunctional cells that cosecrete multiple cytokines ( Fig. 7D ) . Quantifi cation of the extent of heterogeneity using the Simpson diversity index showed that nonmutant CD45.1-positive and Jak2 V617F -positive, CD45.2-positive cells of diseased mice featured a signifi cant increase in the heterogeneity of single-cell secretion (CD45.1: 0.64 vs. 0.43, CD45.2: 0.74 vs. 0.44). Consistent with these data and with our data in the MPL W515L model, ruxolitinib treatment normalized cytokine expression from CD45.1-negative and CD45.2-positive cell populations in the Jak2 V617F knockin transplantation model (Supplementary Fig. S15 ). We next sought to investigate whether mutant and nonmutant cells in PMF could contribute to aberrant cytokine secretion. We identifi ed a patient with PMF with a JAK2 V617F -mutant allele burden of 38%, consistent with partial involvement of the hematopoietic compartment of JAK2 V617F -mutant Number of cytokines secreted 
Relative mRNA expression compared to GFP Table S2 ). Notably, in this patient we found that 59% of the hematopoietic cells secreted one or more cytokines from our measurement ( Fig. 7E ) . Moreover, the frequency of multifunctional cells secreting two or more cytokines was signifi cantly elevated in the patient ( Fig. 7F ) . The proportion of cytokine-secreting cells was greater than expected on the basis of JAK2 V617F -mutant allele burden, suggesting that in this patient, a subset of JAK2 V617F wild-type has to contribute to cytokine production. Taken together, these data illustrate the heterogeneity of aberrant cytokine secretion in MPN models and patients, and that aberrant infl ammatory signaling from more than one population contributes to MPN pathogenesis and therapeutic response.
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DISCUSSION
Although MPNs present as chronic myeloid malignancies, the quality of life and overall survival of patients with PMF is more similar to advanced malignancies, including metastatic epithelial tumors. Patients with PMF have markedly elevated levels of proinflammatory cytokines, which are thought to contribute to PMF-associated symptoms and sequelae ( 12, 13 ) . Clinical data show that JAK inhibition reduces constitutional symptoms and splenomegaly in patients with PMF and post-PV/ET myelofibrosis, concurrent with a reduction in circulating cytokine levels ( 13 ) . Although the prognostic value of circulating cytokine levels in myelofibrosis has been previously demonstrated ( 12 ) , the mechanisms that govern aberrant cytokine production in myelofibrosis and the source of aberrant cytokines in myelofibrosis have not previously been demonstrated. Here, we show that JAK-STAT activation in malignant and nonmalignant cells contributes to myelofibrosis pathogenesis, and that cytokine production by both populations is an important feature of myelofibrosis.
In this study, we demonstrate that JAK1/2 inhibition leads to a rapid, potent reduction in serum cytokine levels, consistent with the rapid clinical benefits seen with JAK inhibitor therapy, and demonstrate that this is a direct effect of JAK kinase inhibition on cytokine production. Single-cell cytokine analysis showed that hematopoietic cells from myelofibrosis models and patients with PMF aberrantly secrete a spectrum of inflammatory cytokines. We performed multiplex, highly sensitive measurements of cytokine secretion from over a thousand captured, viable single cells. The results demonstrated that hematopoietic cells in myelofibrosis show significant upregulation of a spectrum of proinflammatory cytokines, elevation of cellular heterogeneity in cytokine secretion, and increased multifunctional cytokine production, which are not observed in normal hematopoietic cells. Our data on a specific lineage, myeloid, demonstrated that both mature and progenitor myeloid cells contribute to increased cytokine production, and more interestingly that they show distinct cytokine profiles, suggesting their different roles in myelofibrosis pathogenesis. Future studies will delineate the role of additional cytokines in inflammatory signaling in MPN, and use single-cell profiling to analyze nonhematopoietic cell types and previously unexplored hematopoietic lineages, such as lymphoid cells and purified stem cells, in MPN models/patient samples and in other malignancies to determine whether multifunctional cytokine secretion is observed in other malignant contexts.
Many studies have identifi ed JAK2 mutations in patients with MPN and in other malignancies, and several known JAK2 signaling mediators have been linked to MPN disease manifestation and progression ( 21-23 ) ; however, the role of STAT3 signaling in MPN pathogenesis and in infl ammatory signaling in myeloid malignancies has not been previously delineated. STAT3 represents a key link between cancer and infl ammation, and as such provides an ideal candidate signaling effector driving cytokine production in vivo . In this study, we demonstrate a critical role for STAT3 in infl ammatory cytokine production in myelofi brosis. Pan-hematopoietic Stat3 deletion improved survival, reduced disease severity, and reduced cytokine secretion, with similar effi cacy as observed with ruxolitinib therapy. In contrast, restricting loss of Stat3 to the malignant clone did not reduce disease severity or cytokine production, demonstrating that STAT3 signaling must be inhibited in malignant and nonmalignant cells to achieve clinical effi cacy. Consistent with these fi ndings, we discovered that malignant and nonmalignant cells aberrantly secrete infl ammatory cytokines and that JAK inhibition reduces cytokine production from both populations. Our results demonstrate that JAK-STAT3-mediated cytokine production from malignant and nonmalignant cells contributes to MPN pathogenesis and that JAK inhibition in both populations is required for therapeutic effi cacy. These data reveal an important, unexpected mechanism of action of JAK inhibition in MPN, such that the target must be inhibited in tumor and nontumor cells to achieve clinical benefi t.
Recent studies in MPN models and in other hematologic malignancies have shown that additional, nonhematopoietic populations can infl uence malignant transformation, including nestin-positive stromal cells, osteoblasts, and other cell types in the hematopoietic niche (24) (25) (26) . The role of cytokine secretion from these additional populations, particularly at single-cell resolution, has not been explored to date. We believe that single-cell cytokine profi ling can be used to elucidate the specifi c role of different niche populations in normal and malignant hematopoiesis and to assess the impact of JAK inhibitor therapy on the nonhematopoietic microenvironment in model systems and in primary patient samples, which should be the subject of subsequent investigations into cytokine secretion in different malignant states.
Taken together, our data underscore the critical role of aberrant cytokine signaling mediated by STAT3 activation in MPN pathogenesis. Most importantly, our studies support the notion that JAK kinase inhibition in malignant and nonmalignant cells is required to achieve clinical effi cacy in myelofi brosis. Recent data have suggested that ruxolitinib improves overall survival in patients with pancreatic cancer with evidence of systemic infl ammation. As such, inhibition of cytokine signaling in malignant and nonmalignant cells might offer clinical benefi t in other malignancies characterized by aberrant infl ammatory signaling. We hypothesize that www.aacrjournals.org Kleppe et al.
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JAK inhibition may have a broader role in cancer therapy, and that this therapeutic approach may improve outcomes for patients with malignancies characterized by systemic infl ammation.
METHODS
Patient Material
Patient studies were conducted in accordance with the Declaration of Helsinki. Primary patient samples were collected from patients with myelofi brosis and control healthy donors under Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY) Institutional Review Board Protocol 09-141. Ficoll technique was applied to isolate granulocytes from the peripheral blood of patients with myelofi brosis and healthy control individuals. JAK2 allele burden for patients with myelofi brosis was calculated using targeted sequencing approaches (RainDance, MiSeq).
Reagents and Transgenic Mice
Ruxolitinib was provided by Incyte/Novartis and formulated for administration by oral gavage as previously described ( 27 ) . Conditional Stat3 knockout, Jak2 V617F knockin, and germline Il6 knockout mice have been described previously ( 15 , 28 ) . Floxed mice were crossed to the interferon-responsive Mx-Cre and VavCre deleter lines. Congenic mice (CD45.1) used as recipients in transplant studies were purchased from The Jackson Laboratory. Antibodies used for Western blotting included phosphorylated and total JAK2, STAT3, STAT5, and MAPK (Cell Signaling Technology). Mutant (GFP-positive) and wild-type (GFP-negative) populations were separated by FACS using GFP and/or specific cell-surface marker: phycoerythrin (PE)-conjugated CD11b, allophycocyanin (APC)-conjugated Gr1, TER119 (APC-CY7), CD71 (PE-CY7), PE-conjugated CD117, Pacifi c Blue (PacBlue)-conjugated CD16/CD32, phycoerythrin-Cy7 (PeCy7)-conjugated Sca-1, and APC-conjugated CD34. All plasmids used in this study have been previously described ( 29 ) . Lineage-positive (LIN + ) and lineagenegative (LIN − ) subpopulations were separated using a panel of APC-CY7-conjugated antibodies that recognize all mature hemato poietic lineages (CD4, CD19, CD11b, Gr1, TER119, CD3, B220, and NK1.1).
Bone Marrow Transplantation Model
All animal experiments were performed in accordance with our MSKCC Institutional Animal Care and Use Committeeapproved animal protocol. Animal care was in strict compliance with institutional guidelines established by the MSKCC, the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, 1996) , and the Association for Assessment and Accreditation of Laboratory Animal Care International. MPL W515L bone marrow transplantation experiments were performed as described previously ( 14 ) . Briefly, prestimulated c-KIT enriched bone marrow cells were subjected to two rounds of cosedimentation with viral supernatant containing MSCVhMpl W515L -IRES-GFP or empty MSCV-IRES-GFP control vector. A total of 1 × 10 6 cells (∼25%-40% GFP-positive, MPL-expressing cells) were injected into the tail veins of lethally irradiated syngeneic mice. For secondary Jak2 V617F ; Vav-Cre bone marrow transplantations, 5 × 10 6 bone marrow cells harvested from sick Jak2 V617F knockin mice were injected into the tail veins of 8-weekold syngeneic mice ( 15 ) . Engrafted mice were monitored daily for signs of illness, and nonlethal bleeds were performed biweekly to follow up disease progression. Mice showing signs of being moribund, having more than 10% weight loss, or having palpable splenomegaly extending across the midline were sacrificed.
Spleens were removed and weighed, and single-cell suspensions were prepared for subsequent cell staining and fractionation, Western blot analysis, or histopathologic analysis. Peripheral blood chimerism was routinely determined 14 days after bone marrow transplantation. Stat3 excision was confirmed by Western blot analysis and quantitative real-time PCR analysis on red cell lysed peripheral blood samples.
Inhibitor Experiments
At fi rst signs of disease, mice were randomized to begin 14 or 21 days of treatment with the JAK1/2 inhibitor ruxolitinib [90 mg/kg (Balb/c, Mpl W515L ) or 60 mg/kg (C57/BL6, secondary Jak2 V617F recipient mice), p . o ., twice a day] or vehicle followed by measurement of plasma cytokine levels. Mice were ranked on the basis of baseline WBC count and assigned to treatment groups to achieve congruent WBC profi les. Serum was collected 4 hours after last drug administration. For kinetic studies, mice assigned for short-term drug treatment received only three doses, which were administered simultaneously with the last doses of the long-term treatment arm.
Luminex Technology
Luminex assays were carried out using the FlexMAP 3D multiplexing platform (Luminex xMAP system). Plasma levels of 32 cytokines were measured simultaneously using the Millipore Mouse Cytokine 32-plex kit. Serum samples were prepared following manufacturer's instructions. xPONENT (Luminex) and Milliplex Analyst Software (Millipore) was applied to convert mean fl uorescent intensity values into molecular concentrations by the use of a standard curve (5-parameter logistic fi tting method).
Histopathologic Analysis
Femur and spleen samples were fixed in 4% paraformaldehyde overnight and then embedded in paraffin as previously described ( 30 ) . Paraffin sections were cut on a rotary microtome (3-μm; Mikrom International AG), spread in a 45°C water bath, mounted on microscope slides (Thermo Scientific), and air-dried in an oven at 37°C overnight. After drying, tissue section slides were pro cessed either automatically for hematoxylin and eosin (H&E) staining (COT20 stainer, Medite) or manually for reticulum staining with silver impregnation method kit (Bio-Optica). Slides were scanned with Scanscope XT slide scanner (Aperio). Pictures were taken at a 20× (H&E and reticulin) magnification by using Imascope viewer (Aperio). For the expression analysis of IL8 and phospho-STAT3, 5-μm unstained sections from cases of bone marrow samples were stained on the Ventana Discovery XT per the manufacturer's instructions. The following antibodies were used: goat anti-IL8 antibody from R&D Systems (1:40 dilution), monoclonal rabbit anti-phospho-STAT3 antibody from Cell Signaling Technology (1:50 dilution). Photomicrographs were taken using an Olympus BX41 with DP20 software.
Single-Cell Cytokine Secretion Assay
A high-density antibody barcode was created using a microchannel-guided fl ow patterning technique as previously described ( 16, 17 ) . A polydimethylsiloxane microchip with 20 microfl uidic channels for fl ow patterning was fabricated using a soft lithography technique. After the microchip was bonded with a poly-L -lysine glass slide, the capture antibody for each cytokine was injected into a microfl uidic channel and fl owed through the chip via air pressure (1.8 psi, 12 hours). Antibodies were then immobilized on the glass slide to form the antibody barcode. The subnanoliter microchamber array for single-cell capture is a one-layer polydimethylsiloxane slab fabricated using a soft-lithography method and contains 7,700 ( 16 ) . The antibody barcode glass slide was then put on top of the microchambers. Assembled microchamber arrays were then imaged (Nikon Eclipse Ti) to determine the number of cells in each microchamber by using a custom-made image-processing algorithm. After incubation (24 hours, 37°C in 5% CO 2 ), the cytokine signals from antibody barcode chips were developed via an immuno-sandwich ELISA assay. The slide was scanned with GenePix 4200A (Axon) microarray scanner to collect fl uorescent signals. All fl uorescent scanned images were processed with GenePix software and Excel macro to acquire average fl uorescent signals from each microchamber for all bars in each antibody barcode set, and the fl uorescent signals were matched with the number of cells. Single-cell data were gated on the basis of the background signals to distinguish between cytokine producers and nonproducers. The data were further transformed and normalized to perform multidimensional data analysis as previously described ( 17 , 32-34 ) .
Data Processing and Analysis of Single-Cell Cytokine Assays
For all single-cell secretomic analysis, our custom-built algorithms in Excel, MATLAB, and R-packages were used to process, analyze, and visualize the single-cell cytokine profi les. Briefl y, the predetermined cell numbers of the microchambers were matched with fl uorescence intensity values for each measured protein from corresponding microchambers. The background signals from all zero-cell (empty) microchambers were used to determine the gate to detect cytokine-producing cells and nonproducers. The gating threshold was calculated by (average intensity of all empty microchambers for a given cytokine) + 2 × (standard deviation of all empty microchambers for a given cytokine) ( 34 ) . Any cells with fl uorescence intensity of a specifi c cytokine below the gating threshold were considered nonproducers, and their cytokine intensity values were converted to 0. Any cells with fl uorescence intensity above the gating threshold were considered cytokine-producers and given the cytokine intensity value of (the measured fl uorescence intensity − the average fl uorescence intensity of all zero-cell microchambers for a given cytokine). The gated and background-subtracted cytokine intensity values were log-transformed. To eliminate variability in detection sensitivity and profi le the secretion of all assayed proteins, each protein was normalized by the average intensity and the standard deviation. The number of all cells above the gates and the sum of fl uorescence intensity of a given cytokine were measured to calculate the frequency of cytokine producers and the average cytokine secretion per single cell. For the single-cell analysis of unsorted, whole bone marrow compartment, the data were processed without log transformation. By not conducting log transformation, which signifi cantly suppresses the data range, we could distinguish smaller subsets with unique cytokine profi les from the more heterogeneous and larger unsorted bone marrow cell population. Our statistical analysis and graphical representations of the single-cell secretomic profi les are based on the methods routinely used to analyze large-scale high-dimensional datasets from numerous cell subsets ( 17 , 32-34 ) .
Principal Component, Mutual Exclusivity, and Statistical Analysis
All analyses were performed in R. The PCA was performed using the prcomp R function and visualized with the ggplot2 package. The fi rst two principal components explained 60.1% of the variance. PC3 and PC4 (cumulative proportion of variance 78%) were, similar to PC1 and PC2, mainly defi ned by secretion of TNFα, CCL3, CCL4, CXCL1, and CCL5 ( Supplementary Fig. S1A ). Because PC3 to PC4 covered essentially the same cytokines as PC1 and PC2, we focused on the visualization of the fi rst two PCs. PC5 (83%) was dominated by IL10 secretion. We next tested whether two cytokines were less (mutual exclusivity) or more frequently cosecreted than expected by chance. To this end, we created for each pair of cytokines a 2 × 2 contingency table (secreted only in cytokine A; only in B; in both A and B; in neither A nor B) and obtained a P value with the Fisher exact test. P values were adjusted for multiple testing using the Benjamini-Hochberg correction and a false discovery rate (FDR) < 0.05 was considered signifi cant. FDRs were visualized in a heat map, with pairs of cytokines displaying signifi cant cosecretion colored in red, and mutually exclusive pairs in light yellow. Pairs with cosecretion patterns not signifi cantly different from randomly expected patterns were shown in gray. We further tested whether pairs of cytokines are more or less frequently cosecreted in myelofi brosis mice compared with control mice. We again used a Fisher exact test to obtain P values for the corresponding 2 × 2 contingency table (number of cosecreted cells in myelofi brosis, number of non-cosecreted cells in myelofi brosis, number of cosecreted cells in control mice, number of non-cosecreted cells in control mice). Only cells with at least two secreted cytokines were considered in this mutual exclusivity analysis.
Statistical Analysis
The Student t test was used to compare the mean of two groups. Normality tests were used to test the assumption of a normal distribution. Graphs represent mean values ± SEM. Kaplan-Meier survival analysis and the log-rank test were used to compare survival outcomes between the two groups.
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